Abstract
Plasma and cervicovaginal secretion (CVS) samples were collected from 19 human immunodeficiency virus type 1-infected women on lopinavir- or indinavir-containing regimens. Lopinavir and indinavir were detectable in 29 and 93% of CVS samples, respectively, a finding that may be ascribed to these drugs' differences in protein binding and pK(a). The relationship between lopinavir and indinavir pharmacodynamics and viral evolution in the female genital tract should be assessed over time.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / blood
-
Anti-HIV Agents / pharmacokinetics*
-
Chromatography, High Pressure Liquid
-
Female
-
Genitalia, Female / metabolism*
-
HIV Infections / metabolism*
-
HIV-1*
-
Humans
-
Indinavir / blood
-
Indinavir / pharmacokinetics*
-
Lopinavir
-
Protein Binding
-
Pyrimidinones / blood
-
Pyrimidinones / pharmacokinetics*
-
Vagina / metabolism
Substances
-
Anti-HIV Agents
-
Pyrimidinones
-
Lopinavir
-
Indinavir